CDP571, a humanised monoclonal antibody to tumour necrosis factor  , for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

OP014. A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn’s disease refractory to anti-tumour necrosis factor α: UNITI-1

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjw019.013 ◽

2016 ◽

Vol 10 (suppl 1) ◽

pp. S11-S12 ◽

Cited By ~ 2

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Α ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease

The Lancet ◽

10.1016/s0140-6736(97)80083-9 ◽

1997 ◽

Vol 349 (9051) ◽

pp. 521-524 ◽

Cited By ~ 279

Author(s):

WA Stack ◽

SD Mann ◽

AJ Roy ◽

P Heath ◽

M Sopwith ◽

...

Keyword(s):

Crohn’S Disease ◽

Randomised Controlled Trial ◽

Crohn's Disease ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Controlled Trial ◽

Tumour Necrosis Factor Α ◽

Randomised Controlled ◽

Factor Α ◽

Faculty Opinions recommendation of Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297850.792702851 ◽

2012 ◽

Author(s):

Gwo-Tzer Ho

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718257967.793494565 ◽

2014 ◽

Author(s):

Christian Jorgensen ◽

Yves-Marie Pers

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Gut ◽

10.1136/gutjnl-2011-301668 ◽

2012 ◽

Vol 61 (12) ◽

pp. 1693-1700 ◽

Cited By ~ 810

Author(s):

Wolfgang Hueber ◽

Bruce E Sands ◽

Steve Lewitzky ◽

Marc Vandemeulebroecke ◽

Walter Reinisch ◽

...

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Double Blind ◽

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2005.02336.x ◽

2005 ◽

Vol 21 (4) ◽

pp. 373-384 ◽

Cited By ~ 27

Author(s):

B. G. Feagan ◽

W. J. Sandborn ◽

J. P. Baker ◽

F. Cominelli ◽

L. R. Sutherland ◽

...

Keyword(s):

Monoclonal Antibody ◽

Tumour Necrosis ◽

Controlled Trial ◽

Tumour Necrosis Factor Alpha ◽

Double Blind ◽

Necrosis Factor Alpha ◽

Double Blind Placebo ◽

Humanized Monoclonal Antibody ◽

Factor Alpha ◽

11 Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomised, placebo-controlled, double-blind, multicentre trial

Journal of Crohn s and Colitis ◽

10.1016/s1873-9946(13)60012-4 ◽

2013 ◽

Vol 7 ◽

pp. S5-S6 ◽

Cited By ~ 7

Author(s):

B. Sands ◽

B. Feagan ◽

P. Rutgeerts ◽

J.-F. Colombel ◽

W. Sandborn ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Tumour Necrosis Factor ◽

Induction Therapy ◽

Tumour Necrosis ◽

Multicentre Trial ◽

Double Blind ◽

Tumour Necrosis Factor Antagonist ◽

Factor Antagonist ◽

Faculty Opinions recommendation of Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297850.793505750 ◽

2015 ◽

Author(s):

Vijay Kuchroo

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Double Blind ◽

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-204655 ◽

2014 ◽

Vol 73 (6) ◽

pp. 990-999 ◽

Cited By ~ 364

Author(s):

Christopher Ritchlin ◽

Proton Rahman ◽

Arthur Kavanaugh ◽

Iain B McInnes ◽

Lluis Puig ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Faculty Opinions recommendation of Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717297850.793152976 ◽

2012 ◽

Author(s):

Eduard Stange

Keyword(s):

Monoclonal Antibody ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Controlled Trial ◽

Double Blind ◽